BB Biotech AG Total Liabilities
BB Biotech AG total liabilities. Based on the latest financial reports, BB Biotech AG (BION) has total liabilities worth CHF5.29 Million CHF (≈ $6.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BION financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BB Biotech AG (2003–2025)
Total liabilities of BB Biotech AG from 2003 to 2025. This chart illustrates how BB Biotech AG's total liabilities have evolved over time, based on quarterly financial data. Explore BION long-term investment intensity to see how much of total assets are deployed in long-term investments.
BB Biotech AG Competitors by Total Liabilities
The table below lists competitors of BB Biotech AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SpareBank 1 Østlandet
OL:SPOL
|
Norway | Nkr186.90 Billion |
|
Shenzhen SC New Energy Technology Corp Class A
SHE:300724
|
China | CN¥12.75 Billion |
|
APERAM S.A. NY SHS/1 O.N.
F:7AAN
|
Germany | €3.49 Billion |
|
kakaopay Corp.
KO:377300
|
Korea | ₩3.39 Trillion |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
Thailand | ฿133.00 Billion |
|
Jiangxi Jovo Energy Co. Ltd
SHG:605090
|
China | CN¥5.66 Billion |
|
SmartCentres Real Estate Investment Trust
TO:SRU-UN
|
Canada | CA$5.79 Billion |
|
Bird Construction Inc.
TO:BDT
|
Canada | CA$1.80 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down BB Biotech AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BION asset base.
Liquidity & Leverage Metrics
BB Biotech AG Total Liabilities Ratios Explained
BB Biotech AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BB Biotech AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BB Biotech AG (2003–2025)
The table below shows the annual total liabilities of BB Biotech AG from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF6.97 Million ≈ $8.82 Million |
-94.24% |
| 2024-12-31 | CHF121.11 Million ≈ $153.11 Million |
-61.42% |
| 2023-12-31 | CHF313.94 Million ≈ $396.90 Million |
-14.52% |
| 2022-12-31 | CHF367.25 Million ≈ $464.31 Million |
+3.45% |
| 2021-12-31 | CHF355.00 Million ≈ $448.82 Million |
+463.49% |
| 2020-12-31 | CHF63.00 Million ≈ $79.65 Million |
-61.01% |
| 2019-12-31 | CHF161.59 Million ≈ $204.30 Million |
-20.13% |
| 2018-12-31 | CHF202.33 Million ≈ $255.80 Million |
+104.12% |
| 2017-12-31 | CHF99.12 Million ≈ $125.32 Million |
-55.59% |
| 2016-12-31 | CHF223.22 Million ≈ $282.21 Million |
+34.87% |
| 2015-12-31 | CHF165.51 Million ≈ $209.25 Million |
+311.02% |
| 2014-12-31 | CHF40.27 Million ≈ $50.91 Million |
-56.23% |
| 2013-12-31 | CHF92.00 Million ≈ $116.31 Million |
-34.26% |
| 2012-12-31 | CHF139.94 Million ≈ $176.93 Million |
-6.63% |
| 2011-12-31 | CHF149.89 Million ≈ $189.50 Million |
+5.44% |
| 2010-12-31 | CHF142.15 Million ≈ $179.71 Million |
+2972.83% |
| 2009-12-31 | CHF4.63 Million ≈ $5.85 Million |
-95.96% |
| 2008-12-31 | CHF114.37 Million ≈ $144.59 Million |
-63.09% |
| 2007-12-31 | CHF309.83 Million ≈ $391.71 Million |
+2.98% |
| 2006-12-31 | CHF300.86 Million ≈ $380.36 Million |
+37.79% |
| 2005-12-31 | CHF218.35 Million ≈ $276.05 Million |
+5987.26% |
| 2004-12-31 | CHF3.59 Million ≈ $4.53 Million |
-91.76% |
| 2003-12-31 | CHF43.51 Million ≈ $55.01 Million |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more